Table 3.
Key points to remember |
---|
Liver is the most common site of metastasis and prognosis is based on the surveillance and treatment of liver metastasis |
MRI |
The most specific modality for imaging liver metastasis and is at least as sensitive as CT |
Majority of melanoma metastases are not T1 bright. T1 hypointense lesions are aggressive and grow rapidly |
Newer hepatobiliary contrast agents help in detection of very small liver metastases |
Diffusion-weighted imaging is helpful when i.v. contrast cannot be administered |
Treated lesions are also better evaluated with MRI. Decrease in size is not a criterion for response to treatment. Perilesional enhancement does not indicate progression in treated lesions, rather nodular enhancement does |
CT |
Useful for lung metastasis and when MRI is medically contraindicated |
Locoregional treated lesions can be also assessed with CT |
Lesions treated with chemoembolization are assessed by presence of iodized oil in the treated segment. Washout out of the dense material suggests viable tumour |
Ultrasound is mainly useful for biopsy of liver lesions |
PET-CT |
Detects lung nodules and large liver lesions but is insensitive to small liver lesions |
High radiation dose is a major disadvantage |
PET, positron emission tomography.